In terms of source innovation, universities and research institutes focus on fundamental target discovery, while enterprises lead engineering-based translation and implementation. Effective ...
EDMONTON, ALBERTA, CANADA, February 2, 2026 /EINPresswire.com/ — AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha ...
Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, today announced a collaboration agreement with Daiichi Sankyo (TSE: 4568) to ...
AdvanCell and 48Hour Discovery Announce Collaboration and Exclusive Licensing Agreement to Develop a Lead-212 Alpha Radioligand Therapy Program EDMONTON, ALBERTA ...
Under the collaboration, Daiichi Sankyo will work with Leveragen to apply Leveragen’s in vivo antibody discovery capabilities in support of selected research programs. The collaboration reflects a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results